Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model

Abstract Lanatoside C has a promising anti-tumor activity and is a potential candidate for radiosensitizers. In this study, we have investigated the therapeutic efficacy of the combination of 131I-trastuzumab and lanatoside C for inhibition of human epidermal growth factor receptor 2 (HER2) positive...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nagarajan Vinod, Jae Hyung Kim, Seungbum Choi, Ilhan Lim
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c64d0f1d27fe4216be5053777c690572
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c64d0f1d27fe4216be5053777c690572
record_format	dspace
spelling	oai:doaj.org-article:c64d0f1d27fe4216be5053777c6905722021-12-02T17:23:47ZCombination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model10.1038/s41598-021-92460-02045-2322https://doaj.org/article/c64d0f1d27fe4216be5053777c6905722021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-92460-0https://doaj.org/toc/2045-2322Abstract Lanatoside C has a promising anti-tumor activity and is a potential candidate for radiosensitizers. In this study, we have investigated the therapeutic efficacy of the combination of 131I-trastuzumab and lanatoside C for inhibition of human epidermal growth factor receptor 2 (HER2) positive tumor progression in NCI-N87 xenograft model. The combination treatment (131I-trastuzumab and lanatoside C) showed highest cytotoxicity when compared to non-treated control or trastuzumab alone or 131I alone or 131I-trastuzumab alone in vitro. Biodistribution studies using 131I-trastuzumab or combination of 131I-trastuzumab and lanatoside C showed tumor uptake in BALB/c nude mice bearing HER2 positive NCI-N87 tumor xenograft model. The higher tumor uptake was observed in 131I-trastuzumab (19.40 ± 0.04% ID/g) than in the combination of 131I-trastuzumab and lanatoside C (14.02 ± 0.02% ID/g) at 24 h post-injection. Most importantly, an antitumor effect was observed in mice that received the combination of 131I-trastuzumab and lanatoside C (p = 0.009) when compared to control. In addition, mice received lanatoside C alone (p = 0.085) or 131I-trastuzumab alone (p = 0.160) did not significantly inhibit tumor progression compared with control. Taken together, our data suggest that combination of 131I-trastuzumab and lanatoside C might be a potential synergistic treatment for radioimmunotherapy to control the HER2 positive tumor.Nagarajan VinodJae Hyung KimSeungbum ChoiIlhan LimNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Nagarajan Vinod Jae Hyung Kim Seungbum Choi Ilhan Lim Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model
description	Abstract Lanatoside C has a promising anti-tumor activity and is a potential candidate for radiosensitizers. In this study, we have investigated the therapeutic efficacy of the combination of 131I-trastuzumab and lanatoside C for inhibition of human epidermal growth factor receptor 2 (HER2) positive tumor progression in NCI-N87 xenograft model. The combination treatment (131I-trastuzumab and lanatoside C) showed highest cytotoxicity when compared to non-treated control or trastuzumab alone or 131I alone or 131I-trastuzumab alone in vitro. Biodistribution studies using 131I-trastuzumab or combination of 131I-trastuzumab and lanatoside C showed tumor uptake in BALB/c nude mice bearing HER2 positive NCI-N87 tumor xenograft model. The higher tumor uptake was observed in 131I-trastuzumab (19.40 ± 0.04% ID/g) than in the combination of 131I-trastuzumab and lanatoside C (14.02 ± 0.02% ID/g) at 24 h post-injection. Most importantly, an antitumor effect was observed in mice that received the combination of 131I-trastuzumab and lanatoside C (p = 0.009) when compared to control. In addition, mice received lanatoside C alone (p = 0.085) or 131I-trastuzumab alone (p = 0.160) did not significantly inhibit tumor progression compared with control. Taken together, our data suggest that combination of 131I-trastuzumab and lanatoside C might be a potential synergistic treatment for radioimmunotherapy to control the HER2 positive tumor.
format	article
author	Nagarajan Vinod Jae Hyung Kim Seungbum Choi Ilhan Lim
author_facet	Nagarajan Vinod Jae Hyung Kim Seungbum Choi Ilhan Lim
author_sort	Nagarajan Vinod
title	Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model
title_short	Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model
title_full	Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model
title_fullStr	Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model
title_full_unstemmed	Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model
title_sort	combination of 131i-trastuzumab and lanatoside c enhanced therapeutic efficacy in her2 positive tumor model
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/c64d0f1d27fe4216be5053777c690572
work_keys_str_mv	AT nagarajanvinod combinationof131itrastuzumabandlanatosidecenhancedtherapeuticefficacyinher2positivetumormodel AT jaehyungkim combinationof131itrastuzumabandlanatosidecenhancedtherapeuticefficacyinher2positivetumormodel AT seungbumchoi combinationof131itrastuzumabandlanatosidecenhancedtherapeuticefficacyinher2positivetumormodel AT ilhanlim combinationof131itrastuzumabandlanatosidecenhancedtherapeuticefficacyinher2positivetumormodel
_version_	1718380994035187712

Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model

Ejemplares similares